69results about How to "Promote autophagy" patented technology

An application of protocadherin (PCDH) 17 genes belongs to the technical field of genes. On one hand the PCHD17 genes can be used as a mark of early diagnosis of gastric cancer and colorectal cancer and is favorable for early monitoring and prevention of gastric cancer and colorectal cancer, and on the other hand the gene can be used as a new target spot for chemotherapy sensibility detection of gastric cancer and colorectal cancer and is favorable for guiding chemotherapy of gastric cancer and colorectal cancer.

The invention discloses safe and non-irritating eye cream and a preparation method thereof. The safe and non-irritating eye cream comprises the following components: beeswax, cetyl stearyl alcohol, glycerol stearate, PEG-100 stearate, camellia seed fat, hydrogenated polyisobutylene, vitamin E, cyclopentadimethylsiloxane, butyrospermum parkii, ethylhexyl palmitate, carbomer, xanthan gum, hydroxyethyl cellulose, EDTA-2Na, allantoin, betaine, a humectant, hyaluronic acid, glycerol, 1, 3-butanediol, an emulsifier, arginine, p-hydroxyacetophenone, 1, 2-hexanediol, plant extract, acetyl tetrapeptide-5, extract of saussurea lanceolata, extract of chrysanthemum christinae and pure water. The eye cream can effectively lighten black eye circles; in addition, each component of the eye cream is belowEWG three grades, so that the eye cream is natural, has no irritation, is higher in safety, does not increase the burden on the skin of eyes, and does not pollute the environment.

The invention discloses application of a compound tekaning (Chinese character) with a structure in a formula (I) in the specification in preparation of a mitochondrial injury protective agent. In addition, the invention also discloses the mitochondrial injury protective agent of which the effective component is the compound tekaning with the structure in the formula (I). The application fully proves that the compound tekaning, and drugs, drinks or health products containing effective components of the compound tekaning can be used for effectively promoting expression of mitochondrial autophagy key signal molecules, and enhancing mitochondrial autophagy to inhibit the mitochondrial injury, so as to effectively clear mitochondrial dysfunction existing in cortical neuron, especially, dopaminergic neurons of the brain of which the mitochondrial mass is relatively low. Thus, the dopaminergic neuron is protected to play the roles of relieving parkinson's disease and the like and treating a nerve disease.

The invention discloses application of gold nanocages in DAN injury resistance. Experiments prove that the gold nanocages help relieve cellular DNA injury induced by active oxygen, chemotherapeutic drugs (such as hydroxyurea) and physical irradiations (such as ultraviolet and X-ray); in manifesting, the gold nanocages promote proliferative activity of cells with DNA injury and inhibit apoptosis ofcells caused by DNA injury; the gold nanocages can evidently inhibit fibroblast apoptosis caused by ultraviolet irradiation and are applicable to the preparation of anti-aging or anti-radiation cosmetics; the gold nanocages as drug carriers feature optothermal release, never stay in the body for long time, and have good biosafety; X-ray irradiation for a mouse model verifies that the gold nanocages can promote reconstruction of the bone marrow blood-producing system, maintain the steady state of the immune system and extend the survival rate, and are applicable to the preparation of drugs toprevent and treat radiation-caused marrow injury or drugs to treat aplastic anemia.

The invention specifically discloses new application of salidroside, in particularly application of salidroside to the preparation of a Parkin protein agonist drug. By promoting the expression of parkin protein, salidroside, as a Parkin protein agonist, promotes mitochondrial autophagy and mitochondrial homeostasis, inhibiting apoptosis, and thereby the salidroside can be used for treating the neurodegenerative disease and the degenerative disease of the musculoskeletal system.

The invention provides a drug composition for treating acute pancreatitis and application thereof. The composition comprises a fibroblast growth factor 21 (FGF 21), and the fibroblast growth factor 21is used individually or is jointly used with other accessories as an active ingredient. The fibroblast growth factor 21 or the drug composition containing the fibroblast growth factor 21 can be usedfor treating acute pancreatitis, does not antagonize functions of other members of FGF family, and the use safety is very high.

The invention provides a power frequency electromagnetic field generating device having a tumor inhibiting effect. The power frequency electromagnetic field generating device is composed of a power frequency power supply, two auto-transformers, two diode bridges, two groups of coils, a radiation part, a voltage detection part, a magnetic field detection part, a temperature measuring part and a terminal computer. According to the device, on the basis of the power frequency 50 / 60Hz power supply, voltage is continuously changed by virtue of the DC and AC auto-transformers, so that superposed static and alternating electromagnetic fields are generated in the radiation part. A loading method of the electromagnetic fields having the tumor inhibiting effect has a certain extensibility, the frequency is within a range of 30-300Hz, the intensity ratio of the static electromagnetic field to the alternating electromagnetic field is at 0.5-2.5 and total intensity is 1-10mT. The invention provides the special power frequency electromagnetic field generating device and the loading method; the generating device is reasonable in design, capable of acting on organisms, noninvasive and low in toxic and side effects, and the generating device has the obvious inhibiting effect on a plurality of tumors; and due to the action of the magnetic fields, the content of superoxide radicals in cells can be increased, and autophagy is promoted.

The invention discloses an intestinal mucosa repair agent for weaned piglets. The repair agent is prepared from 0.5-2.5 parts by weight of tannic acid, 0.5-1.5 parts by weight of carvacrol, 0.5-1.5 parts by weight of L-carnitine compounds and 6-20 parts by weight of montmorillonite-loaded zinc oxide. Compared with feed which is singly added with the tannic acid, the carvacrol, the L-carnitine compounds or the montmorillonite-loaded zinc oxide, the intestinal mucosa repair agent provided by the invention can reduce the diarrhea rate of the piglets by 75% or above, increase the height of intestinal villi and significantly improve the intestinal absorption and barrier functions of the piglets. The four components have significant interactions in the aspects of promoting intestinal mucosal repair, improving mitochondrial function and promoting mitochondrial autophagy, and have a positive synergistic combination effect. Furthermore, montmorillonite has a controlled release effect on the tannic acid, the carvacrol and the L-carnitine compounds, thus enabling the tannic acid, the carvacrol and the L-carnitine compounds to be easily mixed with the feed and further forming a uniform dispersion system; the repair agent is convenient to use. The intestinal mucosa repair agent for the weaned piglets can significantly protect the mitochondrial function of the weaned piglets and promote theintestinal mucosa repair by means of the synergistic effect of all the components, thereby greatly improving the absorption and barrier functions of the intestinal mucosa.

The present invention relates to antibodies specific for human Beclin-1 protein phosphorylated at position Thr 119 and uses thereof. In particular, these antibodies are useful in diagnosing diseases associated with impaired autophagy including cancer and neurodegenerative diseases. The invention further relates to human Beclin-1 mutated at position 119 with a phospho-mimicking residue and uses thereof for treating cancer and neurodegenerative diseases.

The present invention relates to antibodies specific for human Beclin-1 protein phosphorylated at position Thr 119 and uses thereof. In particular, these antibodies are useful in diagnosing diseases associated with impaired autophagy including cancer and neurodegenerative diseases. The invention further relates to human Beclin-1 mutated at position 119 with a phospho-mimicking residue and uses thereof for treating cancer and neurodegenerative diseases.

The invention discloses applications of a small molecular compound Salubrinal in drugs for treating or preventing osteoporosis and osteopenia diseases. Through the utilization of a mouse model of postmenopausal osteoporosis caused by OVX ovariectomy, a mouse model of disuse osteoporosis caused by tail suspension, in vivo and in vitro analysis of primary bone marrow-derived cells and the indicationof cell line-based experimental results, Salubrinal administration can effectively relieve OVX related symptoms, stimulate the differentiation of osteoblasts and inhibit the development of osteoclasts. Through the indication of precise molecular mechanism of the Salubrinal, the Salubrinal can be applied to drugs for treating or preventing osteopenia diseases caused by postmenopausal osteoporosis,disuse osteoporosis and other factors.

The invention discloses novel application of fluorofenedione in preparing a drug for treating acute kidney injury.

The invention provides an application of USP33 as a medication target in preparation of drugs, and belongs to the field of protein engineering. According to the invention, the deubiquitination enzymeUSP33 interacting with Parkin is discovered by utilizing co-immunoprecipitation and mass spectrometry technologies, so that the USP33 is further discovered to be positioned on the outer membrane of mitochondria, and the E3 ligase Parkin can be modified by deubiquitination. When the USP33 is knocked down, Parkin transposition to mitochondria can be promoted; therefore, mitochondrial autophagy is enhanced to remove damaged mitochondria; USP33 regulates mitochondrial autophagy by influencing deubiquitination of Parkin, apoptosis of nerve cells under MPTP treatment can be inhibited by knocking down USP33, USP33 can be used as a medication target for preparing a medicine, and good application potential and value are achieved.

The present invention relates to at least one modulator of PP2A or at least one modulator of PP2A-like phosphatase or at least one modulator of PP2A and PP2A-like phosphatase or a combination of said modulators for use in the treatment of a disease characterized by an alteration in the DNA damage response. The present invention also relates to a method to identify a subject to be treated with a PP2A modulator comprising detecting in the genome of said patient a mutation in PP2A.

The invention belongs to the technical field of biomedicines and particularly relates to a GOQDs-based pH-response-type bionic nano-preparation and a preparation method and application thereof. The pH-response-type bionic nano-preparation is composed of PEGylated graphene oxide quantum dots, hydrophobic drugs, bionic hybrid membranes and phosphatidylated hyaluronic acid, wherein the hydrophobic drugs are loaded onto the PEGylated graphene oxide quantum dots, the bionic hybrid membranes are camouflaged on outer layers of the PEGylated graphene oxide quantum dots loaded with the hydrophobic drugs, and the phosphatidylated hyaluronic acid is modified on surfaces of the bionic hybrid membranes. The pH-response-type bionic nano-preparation can be used for effectively prolonging the cycle half-life period of the bionic nano-preparation in blood, and enhancing the targeting ability and the controllable release of the bionic nano-preparation in a diseased region.

The invention belongs to the technical field of atherosclerosis drugs, and particularly relates to a two-dimensional nanomaterial vascular plaque scavenger, an M2 macrophage inducer and a cell autophagy modulator. Three atherosclerosis drugs all adopt boron alkene nanoparticles and / or black scale nanoparticles as main components. The two-dimensional nanomaterial atherosclerosis drugs provided by the invention can promote the autophagy process of cells through the peroxidation effect of surface active groups, can induce more M2 macrophages to be released in the degradation process, can purify blood through the physical adsorption effect, and can increase the flowability of blood, and therefore, the effect of quickly removing atherosclerosis lesion lipid waste to intervene and control plaqueformation can be achieved. Meanwhile, the black phosphorus nanoparticles and the boron alkene nanoparticles also have very good biological activity, biocompatibility and natural degradability, and donot cause any drug damage to a human body.

The invention relates to the technical field of biological medicines. According to the invention, peripheral plasma of a patient with multiple myeloma is subjected to microRNAs expression profile analysis, and based upon qPCR technical verification, it discovers that the expression level of miR-145-3p in the peripheral plasma of the patient with the multiple myeloma is significantly reduced in comparison that in normal and healthy people. In addition, by conducting miR-145-3p over-expression and miR-145-3p silencing and by observing cell apoptosis and autophagy levels, results show that the miR-145-3p is capable of promoting cell apoptosis and autophagy. The invention provides a novel serum marker for the diagnosis of the multiple myeloma disease and also provides a novel target for the prevention and treatment of the multiple myeloma disease.

The invention discloses a compound (E)-1,3,3-trimethyl-2-(2-(4-methylbenzo[4,5]imidazo[1,2-a]pyridine-3-yl)vinyl)-3H-indolium-1- iodide in preparing a drug for inhibiting A549 lung cancer cell growthand promoting the apoptosis of A549 cells and autophagy, wherein the drug dose capable of effectively promoting A549 cell apoptosis and autophagy is 1-10 [mu]M, preferably 5-10 [mu]M. The compound isexpected to serve as an effective tool for inhibiting tumor growth and lay a foundation for developing therapeutic drugs for non-small cell lung cancer.

The invention discloses application of compound (E)-2-(5,5-dimethyl-3-(4-(piperazin-1-yl)styrene)cyclohex-2-ene-1-methylene)malononitrile in drugs to inhibit the growth of A549 cancer cells and promote A549 apoptosis and autophagy; the dose of the drugs to effectively promote A549 apoptosis and autophagy is 5-10 mu M. The compound provided herein is expectedly applicable as an effective tool to inhibit tumor growth, and basis is laid for the development of non-small lung cancer therapeutics.

The invention discloses a culture medium additive for preparing autophagosome-type tumor vaccine. A freeze-dried powder preparation comprises one group of compositions, and the compositions comprise a proteasome inhibitor, an autophagy inducer, a lysosomal alkalifier, an excipient, and an antioxidant. The culture medium additive for preparing autophagy small-body-type tumor vaccine and a preparing method thereof have the remarkable advantages that the additive compositions comprise the proteasome inhibitor, the lysosomal alkalifier and the autophagy inducer which synthesize with one another, on one hand, a proteasome degradation pathway and an autolysosome degradation pathway of a tumour cell can be inhibited simultaneously so that tumour antigens can be preserved; on the other hand, autophagosomes are induced to take shape, thus a large quantity of tumour antigens are preserved in the autophagosomes, and then the autophagosomes-type tumor vaccine can be prepared by extracting the autophagosomes.

The invention relates to the technical field of new application of medicines, in particular to new application of doramectin in treatment of gliomas. Through in-vivo and in-vitro experiments, the anti-glioma effect of the doramectin is investigated. The doramectin can inhibit proliferation and migration of glioma and promote apoptosis and autophagy of glioma cells. Therefore, the doramectin can beused for preparing the medicine for treatment of the glioma, and has a good effect on treatment and prognosis of the glioma.

The invention discloses application of a TGF-beta 1 inhibitor in the preparation of drugs to treat diabetic bone healing disorder and belongs to the technical field of biopharmacy. A series of studiesby the inventor verifies that the TGF-beta 1 inhibitor can promote autophagy of diabetic bone marrow mesenchymal cells so as to inhibit cell senescence, thereby giving rise to the ability to promoteosteogenic differentiation. Therefore, the TGF-beta 1 inhibitor is applicable to the preparation of drugs to promote the osteogenic differentiation of diabetic bone marrow mesenchymal cells or drugs to promote diabetic bone healing. The problem is solved effectively herein that drugs to treat diabetic bone healing are absent in the prior art.

The invention provides an application of a mesenchymal stem cell exosome in preparation of preparations for promoting mitophagy. By preparing an exosome derived from the adipose mesenchymal stem cells, Western Blot and flow experiments at the cell level confirm that the regulation and control effect of AMSC-Exo on the mitophagy of parenchyma cells and immune cells; at the same time, in-vivo experiments confirm the effect of the AMSC-Exo on mitophagy pathway in liver tissue; and biological preparations or medicaments for promoting mitophagy are further prepared. Meanwhile, by modifying the AMSC-Exo, the effect for promoting mitophagy of the AMSC-Exo is further improved. The exosome can promote mitophagy and correct mitochondrial dysfunction; has mitophagy promoting effect on both parenchymacells and immune cells; can be used for preparing preparations or medicines for treating diseases related to mitochondrial dysfunction; and can further improve ability for promoting the mitophagy after specific modification.

The invention discloses application of an autophagy inhibitor to preparation of a medicament for reinforcing the anti-hepatoma activity of lycorine. Experiments prove that the lycorine promotes autophagy of hepatocellular carcinoma; a hepatoma cell apoptosis rate in a case of combination of the autophagy inhibitor and the lycorine is higher than the sum of a hepatoma cell apoptosis rate in a caseof independent application of the autophagy inhibitor and a hepatoma cell apoptosis rate in a case of independent application of the lycorine; the autophagy inhibitor and the lycorine generate a synergistic effect in the aspect of resisting to hepatoma; the autophagy inhibitor reinforces the anti-hepatoma activity of the lycorine. The autophagy inhibitor can take an important effect in the treatment on hepatoma.

The invention discloses an application of rapamycin in promotion of neural stem cell amplification. The application limitation that the rapamycin is only used as an immunosuppressor at present is overcome, the rapamycin can remarkably enhance the amplification capacity of neural stem cells, and the rapamycin can be used for treating Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic cerebral apoplexy, brain and spinal cord injury and other diseases.

The invention discloses a medicine for inhibiting stearoyl-CoA desaturase 1, and belongs to the technical field of medical biotechnology. It is found for the first time that the compound with the structure shown in the formula I has the effect of inhibiting stearoyl-CoA desaturase 1, the activity of saturated fatty acid desaturase can be inhibited, the compound plays a role in adjusting fatty acid composition, and an effective new means and a new approach are provided for treating SCD1 drug target diseases.

The invention provides Longya Lilium and Lithocarpus litseifolius cookies which are prepared from the following raw materials in parts by weight: 20 to 40 parts of Longya Lilium extract; 20-40 parts of lithocarpus litseifolius extract, 40-60 parts of wheat flour, 30-50 parts of oat flour, 10-15 parts of eggs, 5-10 parts of skim milk, 3-7 parts of honey, 3-6 parts of red dates, 1-3 parts of bakingsoda, 5-9 parts of xylooligosaccharide, 2-5 parts of tea polyphenol, 1-3 parts of a food preservatives and 10-15 parts of edible oil. The Longya Lilium and Lithocarpus litseifolius cookies prepared bythe method are crisp in taste and rich in milk flavor, have the health-care effects of lowering three highs, resisting oxidation, allergy and cancer, tranquilizing mind by nourishing the heart, nourishing yin, clearing away the heart-fire, maintaining beauty, keeping young, regulating body functions and the like by adding the Longya Lilium extract and Lithocarpus litseifolius extract, and are popular among consumers.

The invention belongs to the technical field of cosmetics, and relates to a cosmetic composition containing a whitening compound, the cosmetic composition is prepared from the following raw materials by weight: 6-15 parts of nicotinamide, 10-20 parts of anilide, 5-10 parts of panthenol, 8-16 parts of a laminaria saccharina extract, 5-15 parts of transparent vitamin, and 2-10 parts of Botanin. The cosmetic composition containing the whitening compound has the beneficial effects that by adding the nicotinamide, the anilide, the panthenol and the laminaria saccharina extract, melanin generation can be inhibited, meanwhile, the anilide can intercept melanin and inhibit melanin transfer, melanin metabolism is accelerated through the nicotinamide, the whitening purpose is achieved, the vitamins, the Botanin and the low-concentration salicylic acid are added and matched, so that the generation of collagen can be promoted, the metabolism of old and waste cutin can be promoted, the pore blockage condition can be improved, the freckle-fading and freckle-removing purposes are achieved, and the freckle-fading and freckle-removing functions.